of T cells stimulated by Df; ILA and IFN-y production; and defined as normal alertness, no dyspnea or mild dyspnea serum IgE levels. The data reveal a close correlation between (patient was able to speak in complete sentences), no retracimprovement in clinical status and changes in IL2 responsive-tions or mild intercostal retractions, good skin color, wheezing ness. This improvement was also associated with changes in at the end of expiration only, and a peak expiratory flow rate or the ratio of IFN-y:IU synthesis observed after short-term, FEV, that was 70-90% of the predicted or personal best. FEV, antigen-specific restimulation of PBMC in vitro.
did not differ significantly among the groups (Table 1) . Before the study, levels of severity among patients in groups I and I1
MATERIALS AND METHODS
were similar to those in patients in group 111 with mild or Subjects. Lymphocytes were isolated from samples of blood taken from 40 Japanese patients with bronchial asthma (Table  1) . Eight age-matched healthy subjects were used as the control group. Patients with active-disease had recurrent asthma attacks, and positive immediate skin reactions (as defined by an immediate wheal response to a skin prick test) to house dust mite and Df antigen (mite 1, Torii & Co., Ltd. Tokyo, Japan). Serum IgE scores against mite antigen (15) , as determined by RAST, varied from 1 to 4. The diagnostic criteria for bronchial asthma were those defined by the American Thoracic Society. None of the patients was having an asthma attack at the time of the examination, and none was taking oral corticosteroids or anti-allergic agents such as ketotifen (16) . The subjects were divided into three groups. Patients in group I were in complete remission. They were either disease-free (approximately 74%), or had had fewer than two or three mild asthma attacks per year over the previous 2 y without any medication. Patients in group I1 were in partial remission. They had had at least one, but fewer than two or three, mild asthma attacks per year over the previous 2 y despite medication. They were taking 15-20 mg/kg/day of theophylline, or a P2-agonist, or both, either continuously or intermittently. Patients in group I11 had active disease. They suffered more than 10 mild or moderate attacks per year, despite medication such as theophylline, a P2-agonist, anti-allergic agents such as ketotifen, or some combination thereof. The severity of acute exacerbations of asthma and the severity of the disease were estimated according to the Guidelines for the Diagnosis and Management of Asthma, in the National Asthma Education Program; Expert Panel Report of the National Institutes of Health, USA. A mild attack was moderate, but not severe, asthma. Characteristics of the groups are shown in Table 1 . Informed consent was obtained from each patient or from the patient's parents.
Staining/quenching sobtion. A stock solution of PI (Sigma Chemical Co., St. Louis MO, 0.5 mg/mL in 4.9% EDTA) was prepared, and 1.5 mL of this solution were diluted with 7.5 mL of EDTA solution (4.9%, pH 7.0, Wako Pure Chemical Industries Inc., Japan). It was then added to 1.5 mL of Triton X-100 (8%, vol/vol, Wako Pure Chemical Industries Inc., Japan) to lyse the lymphocytes. Drawing ink (0.1 mL of a 2"-fold dilution, Leitz, Wetzlar) was included to quench background fluorescence. This solution was kept at -20°C and was called LSQ medium.
The assay with LSQ medium is based on the observation that living cells contain dsDNA immediately after division, but dead cells contain mainly ssDNA. In LSQ medium, PI attaches to dsDNA rather than to ssDNA derived from the cells lysed by Triton X-100. This difference in the affinity of PI allows one to count the living cells. The ink in the LSQ medium can suppress the background fluorescence of PI.
Assay of T cell responsiveness to ZL2. The growth of T cells incubated with an antigen and then exposed to IL2 was taken as an index of their responsiveness to IL2. The intensity of fluorescence of dsDNA was measured (17, 18) . In brief, 1 X mononuclear cells, separated from heparinized blood by centrifugation on a Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient (19) , were cultured in the presence of Df antigen or 5 ~g / m L of Con A (Sigma Chemical Co., St. Louis, MO), and suspended in 1 mL of RPMI 1640 medium containing 40 pg/mL gentamicin and 10% heat-inactivated IL2 production and assay. Lymphocytes (lo6 cells/mL) stimulated with Df (10 pg1mL) were cultured for 2 d, and then the supernatant was collected. IL2 activity was assayed with the IL2-dependent CTLL line according to the method of Gillis et al. (20) . Test supernatant was added to a final concentration of 50% to cultures containing 5 X ~~" T L L cells in a total volume of 100 pL. Approximately 24 h later, 0.5 pCi of [ ,~] t h~m i d i n e was added. Cultures were harvested 16 h later. One unit of IL2 was defined as the amount obtained from a standard curve of CTLL cell proliferation with r-IL2. The incorporated radioactivity was measured by liquid scintillation counting. The CTLL cells were allowed to propagate in RPMI 1640 medium supplemented with 10% FCS and IL2. When a MAb against human IL2 is added to the supernatant of cultures of lymphocytes taken from patients and stimulated with Df, CTLL indicator cells do not grow (21) . This indicates that IL2, and no other lymphokine, was the active factor being assayed. The sensitivity of this assay was 0.02 unitImL.
Counting of cells producing ZL4. Mononuclear cells (1 X 10" were added to 1 pg/mL of Df antigen or to 5 pg1mL of Con A (Sigma Chemical Co., St. Louis, MO) and suspended in 1 mL of RPMI 1640 medium containing 40 pg1mL of gentamicin and 10% heat-inactivated pooled human serum in a culture tube (Falcon Plastic 2054), and cultured for 3 d (37"C, 10% CO,). An ELISPOT assay was done, as reported elsewhere (22, 23) , to evaluate the ability of these cells to produce IL4. Briefly, 96-well microplates (Linbro, Flow Laboratories, Inc. MacLean, VA) were coated overnight at 4°C with a purified MAb against 1L4 (380-1, Ono Chemical Industries, Osaka, Japan) at a concentration of 30 pg1mL (100 pLIwel1). Control wells were coated with PBS containing 5% FCS. All wells were then blocked with 200 p L of 0.25% gelatin (Wako Pure Chemical Industries, Ltd., Tokyo, Japan) in PBS for 1 h at 37°C. Df-stimulated or unstimulated cells (1 X lo3 to 1 xlo5 cellslwell) resuspended in RPMI 1640 containing 3%
FCS were added to each well (100 pLIwell) and incubated for 16 h (37"C, 10% CO,). The cells were washed three times with PBS and then incubated in 1% BSA-PBS for 2 h at room temperature with 100 p L of a rabbit polyclonal antibody against human IL4 (4 pglmL, BL-4, Genzyme Corp., Boston, MA). The plates were then washed three times with PBS and incubated in 1% BSA-PBS (100 pLIwell) with alkaline phosphatase-conjugated anti-rabbit IgG obtained from goats (diluted 1:1000, 65-6122, Zymed Laboratories, Inc. San Francisco, CA) for 2 h at room temperature. The plates were thcn washed with PBS three times and refilled with 100 p L of a solution of 1 mg/mL alkaline phosphatase substrate, 5-bromo-4-chloro-3-indolyl phosphate (Sigma Chemical Co., St. Louis MO) dissolved at 40°C in 0.6% (wtlvol) agarose (Electlan, 44250, BDH, Poole, England) containing 0.1 M 2-amino-2-methyl-lpropanol, 0.02% (vollvol) Triton X-405 (BDH), and 5.0 mM MgCl,. Spots representing single IL4-secreting cells that developed during 4 h of incubation at 37°C were counted with an inverted microscope. The specificity of the ELISPOT assay for detecting IL4-secreting cells was determined by inhibition with soluble antibody against IL4.
IFN-y production and assay. Mononuclear cells (1 X lo6) were added to graded doses (0.1, 1 .O, 10.0 pg1mL) of Df or to a 5 pg1mL dose of Con A, and suspended in 1 mL of RPMI 1640 medium containing 40 pg/mL of gentamicin and 2% heat-inactivated pooled human serum in a culture tube (Falcon Plastic 2054). Then the cells were cultured for 5 d (37OC, 10% CO,). Culture supernatanis from the cells were harvested and assayed for IFN-y with a slightly modified version of a solid-phase ELISA reported elsewhere (24) . Briefly, 96-well microtiter plates (Linbro, Flow Laboratories, Inc., MacLean, VA) were coated with 100 pLIwell of rabbit antibody against human IFN-y (PIF-3, Hayashibara Biochemical Laboratories, Inc., Okayama, Japan) at 1 pg1mL each in pH 9.6, 0.1 M NaHCO, buffer overnighf at 4°C in a humidified box. The wells were washed and then blocked with 150 p L of 0.25% gelatin (Wako Pure Chemical Irtdustries, Ltd.). A total of 100 p L of undiluted culture supernatant per well were assayed. After 16 h of incubation at 4"C, the wells were emptied and washed three times. Then 1 pg/mL of mouse MAb against human IFN-y (MIF-3, Hayashibara Biochemical Laboratories, Inc., Okayama, Japan) was added to the wells. Thcy were then incubated at room temperature for 1 h. After three washes, goat biotinylated antibody against mouse IgG (Tago, Inc., Burlingame, CA; diluted 113000) was added and allowed to incubate for 1 h. After three washes with PBS, streptavidin-conjugated horseradish peroxidase (Life Technologies, Inc., Gaithersburg, MD) was added to each well, and the plates were incubated at room temperature for 20 min. A total of 100 p L of 0-phenilenediamine (Life Technologies, Inc.) substrate solution was added to the wells after six washes with PBSITween. Absorbance at 492 nm was read with an ELISA reader (Bio-Tek Instruments, Inc., Burlington, VT). Purified human IFN-y (Japan Chemical Research Pharmaceuticals Co., Ltd., Kobe, Japan) was used as a standard. Results are expressed as units of IFN-ylmL of supernatant with reference to a standard IFN-y. The sensitivity of this sandwich ELISA assay was 1 unitImL.
The greatest difference in IFN-y act~~vity between unstimulated cells and Df-stimulated cells from patients with active asthma was observed when the concentration of human serum used in the culture medium was 2%. Therefore, this concentration was used in the culture for IFN-y production.
ZgE measurements. Total IgE levels in serum were measured with a solid-phase ELISA as reported elsewhere (25) . Levels in serum of specific IgE against Df antigen were determined by RAST (15) .
Data analysis. The data were analyzed with the two-tailed t test.
RESULTS

Evaluation of Df-induced responsiveness of T cells to ZL2
and of the production of ZL2 by lymphocytes from patients with asthma. Lymphocytes obtained from patients in group I11 induced Df-specific IL2 responses, in a Df dose-dependent manner (Fig. 1) . These responses were much weaker when they were induced by lymphocytes from normal subjects (p < 0.05, Fig. 1 ). Responses induced by lymphocytes from patients in group I1 were also stronger than those induced by lymphocytes from normal subjects. In contrast, the responses induced by lymphocytes from patients in group I were similar to those induced by lymphocytes from normal subjects (Fig. 1) . In groups I and 11, IL2 responses were weak, the patients had fewer symptoms, and the symptoms were not severe. Older patients who still had symptoms (group 111) were responsive. The intensity of the response was not related to age (data not shown). IL2 production by lymphocytes from patients in group I11 was much greater than that of lymphocytes from normal subjects. It was also greater than that of lymphocytes from patients in remission (groups I and 11, Fig. 2) . Collectively, the data indicate that T cell responses induced by Df were markedly weaker in the patients in remission than in those with active disease. Production of Z U by lymphocytes from patients. The number of cells producing IL4 was approximately 5-fold higher in patients with active asthma (group 111) than in nonasthmatic subjects (Fig. 3) . The production of IL4 induced by Df in patients with active asthma was dose-dependent; 1 pg/mL IL4 induced the maximal response (data not shown). Con A also induced production of cells that secreted IL4, up to a number similar to the Df-induced spot number. There were no differences in the spot numbers between lymphocytes from patients (36.3 2 14.3 (SE) ~~o t s / l 0~ cells, n = 9) and from normal individuals (42.6 5 4.4 (SE) ~~o t s / 1 0~ cells, n = 6) when stimulated with Con A. After in vitro stimulation with Df antigen, the frequency of Df-reactive cells producing IIA from patients in remission (groups I and 11) was significantly lower than that from patients with active disease (group 111, Fig. 3) . Thus, the ability of lymphocytes from patients in remission to secrete IL4 when stimulated with Df antigen was downregulated.
Production of ZFN-y by lymphocytes from patients. In the absence of in vitro stimulation with Df antigen, production of a, no remission (n = 15); 0 , age-matched normal subjects (n = 7); * p < 0.01
(compared with normal subjects and patients in complete or partial remission).
UP-REGULATED IFN-7 PRODUCTION IN ASTHMA IN REMISSION
IFN-y by lymphocytes from patients and from normal subjects was essentially equivalent (Fig. 5) . In the presence of Df antigen, the production of IFN-y by lymphocytes from patients with active disease (group 111) was dose-dependently inhibited (Figs. 4 and 5 ). This was not true of lymphocytes from normal subjects. Production of IFN-y by lymphocytes from the patients with active asthma who were allergic solely to Df was not iilhibited by ovalbumin or Japanese cedar antigen (Fig. 4) . In contrast, production of IFN-y by lymphocytes from patients allergic solely to ovalbumin or Japanese cedar antigen was lower after stimulation with these substances (data not shown).
These results indicate that Df-induced inhibition of the production of IFN-y in patients with asthma was specific to the antigen. Moreover, IFN-y production by cells from patients in complete remission (group I) was markedly higher after antigen-driven restimulation (Fig. 5 ), but that was not true of IFN-y production by cells from patients with active disease (group 111) or in partial remission (group 11). After in vitro stimulation with Con A, IFN-y synthesis did not differ among the groups (Fig. 5) . Collectively, the data indicate that after exposure to Df antigen the IFN-y responses of patients in complete remission can increase. Serum ZgE levels in asthmatic subjects. Total serum IgE levels of patients in complete remission were significantly lower than those of patients with active disease (Table 1) . Df-specific IgE levels in asthmatic subjects correlated only weakly with clinical improvement (data not shown). However, there were no statistically significant differences in RAST scores (Table 1) .
DISCUSSION
The highest incidence of bronchial asthma is during the first several years of life (5) . Asthma is rarely diagnosed during adolescence and almost all patients become asymptomatic by OVA 0 1 10 100 that time. In almost all children and young adults with asthma, mite antigen skin tests are positive (5, 7). In contrast, asthma first diagnosed later in life (after the age of 40 y) often has no clear relationship to atopy and is geinerally associated with persistent symptoms (1). To better understand the immunologic mechanisms of childhood asthma attacks caused by exposure to mite antigen, we evaluated a number of immunologic factors in adolescents who were in remission and in others who still had frequent asthma attacks.
Concentration
In vitro testing of T lymphocytes activated by antigens is an important way to study T cell-dependent responses in allergic subjects (8) (9) (10) (11) . Previously, the presence and activity of such lymphocytes were studied primarily via measurement of proliferation of freshly derived PBMC in response to allergens (26, 27) . More recently, cytokine production in response to allergen-specific stimulation has been measured (28). This approach, in which freshly derived n'ormal T cells are used instead of long-term T cell clones, has generally yielded weak responses, so the results are difficult to compare with those from T cells freshly derived from nonatopic and allergic subjects. Acquisition of IL2 responsiveness by allergenstimulated PBMC is essential for T cell activation (8) (9) (10) (11) (12) (13) (14) . We previously reported that allergens can induce responsiveness to IL2 in T lymphocytes freshly derived from allergic subjects, but not in those derived from normal subjects (18, (29) (30) (31) (32) . We showed that this sensitive measure of in vitro T cell reactivation could be used to identify sensitizing allergens and to monitor clinical activity of the disease (17, 18, 29, 30) .
In this study, Df-induced T cell activation (as measured by IL2 responsiveness) occurred in PBMC freshly derived from patients with asthma, after short-term stimulation with Df antigen; but it did not occur in PBMC: from normal subjects. The Df-specific responses to IL2 in cells from patients in complete or partial remission were very weak. Similarly, when measured in vitro, IL2 production induced by Df was signifi-cantly lower in samples from those patients than in samples from patients with active disease. Cells stimulated with Con A became responsive to IL2; they divided approximately 2-3-fold in 8 d. Df-activated lymphocytes from patients also became responsive to IL2, and the number of cells increased in the same fashion. In contrast, unstimulated lymphocytes cultured for 5 d did not proliferate (as measured by the intensity of fluorescence), and the number of living cells did not increase, even when r-IL2 was added to the cell suspension over a 3-d-long second culture. In contrast, unstimulated cells took up more [%I]T~R when stimulated with r-IL2 than without r-IL2. Thus, IL2 responsiveness (as measured by [ 3~]~d~ uptake) increased to an degree similar to that seen in the cells activated by antigen. This is why the [ 3~]~d~ uptake method for evaluating antigen specificity of the induced IL2 responsiveness of activated cells could not substitute for counting of cells stained by PI (17, 18) .
IL4 has been shown to be essential for IgE production both in animals and in humans (33) (34) (35) . The ratio of IL4:IFN-y synthesis after exposure to an antigen may determine whether that exposure causes hypersensitivity or tolerance. Consequently, we directly examined the capacity of fresh PBMC from normal and asthmatic subjects to synthesize ILA and IFN-y after antigen-specific restimulation in vitro. The data revealed very high levels of IL4 synthesis and low levels of IFN-y synthesis in patients with active asthma (group 111). In contrast, patterns of cytokine synthesis in patients who were in complete or partial remission were similar to those in normal subjects. This association between the patterns of in vitro cytokine synthesis in patients in remission and improvement in their clinical status is intriguing; it provides strong, albeit indirect, support for the hypothesis that the ratio of 1LA:IFN-y synthesis by antigen-specific T cells affects the intensity of hypersensitivity.
When stimulated with Df antigen, the cells from patients with active disease produced less IFN-y and more IL4 than did nonactivated cells. The Df-induced inhibition of IFN-y production by cells from patients with active disease was blocked by anti-IL4 antibody, and production of IFN-y returned to a level similar to that of nonactivated cells (our unpublished data). Anti-IL4 antibody did not influence IFN-y production by nonstimulated cells (our unpublished data). Df-induced production of IFN-y by lymphocytes from normal subjects was suppressed by recombinant IL4 in a dose-dependent manner (our unpublished data). One reason for the decrease in Dfinduced production of IFN-y may be secretion of regulatory cytokines, such as IL4, by Df-reactive cells. The ability of ILA and IFN-y to cross-regulate one another's synthesis (13, 36) is still a topic of much debate and has been studied in animals and humans. However, it is tempting to speculate that changes in the balance of cytokine synthesis in adolescents with asthma may improve their clinical status and decrease IgE production.
An intriguing finding of this study was the high level of antigen-stimulated production of IFN-y by lymphocytes obtained from Df-insensitive patients in complete remission (group I). These data suggest that clinical unresponsiveness reflects not anergy but active inhibition of IgE induction, which may be caused by antigen-driven processes such as IFN-y synthesis. One interpretation of our data are that C D~+ T cells shift from Th2 type to T h l type (9, 12, 13) . The mechanisms of such a shift remain unclear. However, when stimulated with a specific antigen, a resting C D~+ T perentiates into a pluripotential Tho cell. Under the influence of additional factors, such as exogenous lymphokines and costimulatory molecules expressed by cells that present antigens, the Tho cell differentiates into a mature T h l or Th2 effector cell (37) . Cytokines such as IL12 (38) and IFN-y (39), or a difference in the cells that present antigens (40, 41) , or both, may be involved in the mechanisms by which T h l cells predominate in patients in complete remission.
In this study, T cell activation (as determined by Df-induced responsiveness to IL2) was low in patients in remission. This finding conflicts with the production of IFN-y by these cells. We did not determine whether the frequency of Df-reactive cells in the PBMC of these patients was similar to that in normal subjects, or was lower than that in patients with active disease. However, in patients in remission Df antigen may be able to induce Thl-type clonal anergy and to induce Thl-type clones that produce cytokines such as IFN-y. This hypothesis is supported by the following finding: after antigen-presenting cells are activated, IL12 can increase the production of IFN-y in anergic cells without causing proliferation, and this production of IFN-y by anergic cells can occur even in the absence of IL12 (42) . The cytokine IL12 is produced by macrophages and B cells (43) . It stimulates the proliferation of T cells after they are activated, induces the production of IFN-y (38) , and is important in predominantly Thl-like responses in T cells (44) . We did not study IL12 receptors or the ability of cells from patients in remission to produce IL12. However, IL12 might cause Df-induced anergic cells to produce IFN-y without causing cell proliferation.
The effects of treatment with recombinant IFN-y in allergic disease are controversial. In one study, IFN-y did not inhibit IgE in vivo in patients with allergic rhinitis and had minimal effects in patients with atopic dermatitis (45) . Administration of IFN-a and IFN-y to patients with hyper-IgE syndrome can transiently reduce IgE levels (46, 47) . We found no direct evidence that IFN-y suppresses 114-driven IgE production among patients in remission. However, in vitm suppression of IgE production by IFN-y (35, 36, 48) may be important in the treatment of allergic diseases such as mite antigen-induced asthma. The low level of IL2 responsiveness and subsequent changes in the pattern of cytokine production by Df-stimulated lymphocytes from patients with Df-induced asthma in remission might be used to lower IgE levels, which would suggest a strategy for the use of IFN-y to treat asthma.
Recombinant cytokines may become available for clinical studies. In the present study, production of IFN-y by Dfstimulated lymphocytes from patients with active asthma was low, but production by lymphocytes from patients in remission was high. These data indicate that recombinant IFN-y may be useful as an adjunct to immunotherapy in bronchial asthma. Work to be reported in the near future may define the clinical role of cytokines.
